Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as multiple sclerosis (MS), lymphoma, neurological diseases, and rheumatoid arthritis.
In July 1999, Biogen Idec contracted with Fluor to design, build, and validate a 250,000-square-foot LSM plant with the capability to run up to 120,000 liters of bioreactor capacity.
At the time, LSM was one of the largest cell culture manufacturing facilities in the world that can produce multiple products. The project expanded Biogen Idec's capacity to quickly launch new products and set new standards in the biotech industry for production cost-efficiency and flexible multiproduct operations.
The LSM facility includes cell culture processing, purification, process support, and clean utilities including clean in place (CIP).